Spots Global Cancer Trial Database for tare
Every month we try and update this database with for tare cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma. | NCT05451862 | Hepatocellular ... | Holmium-166 tre... Holmium-166 wor... | 18 Years - | Terumo Europe N.V. | |
| Taking AIM at Breast Cancer | NCT04720209 | Breast Cancer Breast Cancer S... Breast Cancer S... Breast Cancer S... | CARE TARE Home-Based Stre... | 18 Years - | Dana-Farber Cancer Institute | |
| Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients | NCT06332079 | Colorectal Canc... | 166Holmium TARE Cetuximab Panitumumab 5-Fluorouracil Bevacizumab Capecitabine | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients | NCT06332079 | Colorectal Canc... | 166Holmium TARE Cetuximab Panitumumab 5-Fluorouracil Bevacizumab Capecitabine | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE | NCT06040099 | Hepatocellular ... | Durvalumab Bevacizumab Transarterial R... | 18 Years - 130 Years | AstraZeneca | |
| 11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE | NCT02519075 | Hepatocarcinoma | No intervention | 18 Years - | Istituto Clinico Humanitas | |
| Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver | NCT01686880 | Hepatocellular ... Liver Cirrhosis | Sirsphere trans... | 18 Years - | Jules Bordet Institute | |
| Radioembolisation and Chemotherapy in Liver Metastatic Breast Cancer Patients | NCT06142344 | Liver Metastase... Breast Cancer | Quiremspheres⢠| 18 Years - | The Netherlands Cancer Institute | |
| 11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE | NCT02519075 | Hepatocarcinoma | No intervention | 18 Years - | Istituto Clinico Humanitas | |
| A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE | NCT06040099 | Hepatocellular ... | Durvalumab Bevacizumab Transarterial R... | 18 Years - 130 Years | AstraZeneca | |
| MRI-guided Holmium-166 Radioembolization | NCT05609448 | Primary Liver C... Non-Resectable ... | MRI-guided radi... | 18 Years - | Radboud University Medical Center | |
| Radioembolisation and Chemotherapy in Liver Metastatic Breast Cancer Patients | NCT06142344 | Liver Metastase... Breast Cancer | Quiremspheres⢠| 18 Years - | The Netherlands Cancer Institute | |
| Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver | NCT01686880 | Hepatocellular ... Liver Cirrhosis | Sirsphere trans... | 18 Years - | Jules Bordet Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
